Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.22
EXEL's Cash-to-Debt is ranked lower than
71% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. EXEL: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
EXEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 1.47 Max: N/A
Current: 2.22
Equity-to-Asset 0.15
EXEL's Equity-to-Asset is ranked lower than
87% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. EXEL: 0.15 )
Ranked among companies with meaningful Equity-to-Asset only.
EXEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.9  Med: 0.13 Max: 0.79
Current: 0.15
-3.9
0.79
Piotroski F-Score: 6
Altman Z-Score: 3.05
Beneish M-Score: -0.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -14.69
EXEL's Operating Margin % is ranked higher than
65% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. EXEL: -14.69 )
Ranked among companies with meaningful Operating Margin % only.
EXEL' s Operating Margin % Range Over the Past 10 Years
Min: -893.86  Med: -145.27 Max: 30.91
Current: -14.69
-893.86
30.91
Net Margin % -38.92
EXEL's Net Margin % is ranked higher than
57% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. EXEL: -38.92 )
Ranked among companies with meaningful Net Margin % only.
EXEL' s Net Margin % Range Over the Past 10 Years
Min: -1040.57  Med: -113.64 Max: 26.14
Current: -38.92
-1040.57
26.14
ROA % -15.22
EXEL's ROA % is ranked higher than
65% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. EXEL: -15.22 )
Ranked among companies with meaningful ROA % only.
EXEL' s ROA % Range Over the Past 10 Years
Min: -63.23  Med: -31.4 Max: 20.08
Current: -15.22
-63.23
20.08
ROC (Joel Greenblatt) % -1009.51
EXEL's ROC (Joel Greenblatt) % is ranked lower than
60% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. EXEL: -1009.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6260.17  Med: -1065.04 Max: 766.96
Current: -1009.51
-6260.17
766.96
3-Year Revenue Growth Rate 65.00
EXEL's 3-Year Revenue Growth Rate is ranked higher than
90% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. EXEL: 65.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.3  Med: 2.3 Max: 65
Current: 65
-61.3
65
3-Year EBITDA Growth Rate -48.70
EXEL's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. EXEL: -48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.7  Med: -6.25 Max: 17.9
Current: -48.7
-48.7
17.9
3-Year EPS without NRI Growth Rate -40.50
EXEL's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. EXEL: -40.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXEL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.1  Med: -8.45 Max: 16.1
Current: -40.5
-42.1
16.1
GuruFocus has detected 4 Warning Signs with Exelixis Inc $EXEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXEL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EXEL Guru Trades in Q1 2016

Paul Tudor Jones 63,482 sh (New)
Jim Simons 1,008,919 sh (+82.99%)
Charles Brandes Sold Out
» More
Q2 2016

EXEL Guru Trades in Q2 2016

Joel Greenblatt 21,735 sh (New)
Steven Cohen 2,025,400 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 31,445 sh (-50.47%)
» More
Q3 2016

EXEL Guru Trades in Q3 2016

Jim Simons 1,868,450 sh (New)
Joel Greenblatt 130,059 sh (+498.39%)
Steven Cohen 4,132,900 sh (+104.05%)
Paul Tudor Jones 49,374 sh (+57.02%)
» More
Q4 2016

EXEL Guru Trades in Q4 2016

Joel Greenblatt 422,461 sh (+224.82%)
Steven Cohen Sold Out
Jim Simons 1,310,510 sh (-29.86%)
Paul Tudor Jones 25,973 sh (-47.40%)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:UTHR, NAS:BIVV, NAS:IONS, NAS:ARIA, NAS:ALNY, NAS:KITE, NAS:ACAD, NAS:TECH, NAS:GLPG, NAS:JAZZ, NAS:BLUE, NAS:TSRO, NAS:NKTR, NAS:ALKS, NAS:CLVS, NAS:SGEN, NAS:RARE, NAS:ICPT, OTCPK:BTGGF, NAS:CBPO » details
Traded in other countries:EX9.Germany,
Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer as Cometriq and advanced renal cell carcinoma, or kidney cancer, as Cabometyx. Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. In addition, the company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.

Ratios

vs
industry
vs
history
Forward PE Ratio 357.14
EXEL's Forward PE Ratio is ranked lower than
98% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. EXEL: 357.14 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 35.12
EXEL's Price-to-Owner-Earnings is ranked lower than
54% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. EXEL: 35.12 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EXEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.09  Med: 40.72 Max: 2234
Current: 35.12
4.09
2234
PB Ratio 69.44
EXEL's PB Ratio is ranked lower than
99% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. EXEL: 69.44 )
Ranked among companies with meaningful PB Ratio only.
EXEL' s PB Ratio Range Over the Past 10 Years
Min: 2.53  Med: 16.45 Max: 927.5
Current: 69.44
2.53
927.5
PS Ratio 27.49
EXEL's PS Ratio is ranked lower than
65% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. EXEL: 27.49 )
Ranked among companies with meaningful PS Ratio only.
EXEL' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.65 Max: 47.25
Current: 27.49
1.64
47.25
Price-to-Free-Cash-Flow 24.69
EXEL's Price-to-Free-Cash-Flow is ranked higher than
50% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. EXEL: 24.69 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EXEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.31  Med: 21.18 Max: 48.15
Current: 24.69
3.31
48.15
Price-to-Operating-Cash-Flow 24.50
EXEL's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. EXEL: 24.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EXEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.26  Med: 20.85 Max: 46.74
Current: 24.5
3.26
46.74
Current Ratio 1.74
EXEL's Current Ratio is ranked lower than
77% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. EXEL: 1.74 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.42 Max: 5.81
Current: 1.74
0.92
5.81
Quick Ratio 1.73
EXEL's Quick Ratio is ranked lower than
73% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. EXEL: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.42 Max: 5.81
Current: 1.73
0.92
5.81
Days Inventory 161.84
EXEL's Days Inventory is ranked lower than
60% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. EXEL: 161.84 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 161.84  Med: 352.5 Max: 471.76
Current: 161.84
161.84
471.76
Days Sales Outstanding 80.54
EXEL's Days Sales Outstanding is ranked lower than
63% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. EXEL: 80.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 33.29 Max: 80.54
Current: 80.54
4.51
80.54
Days Payable 365.72
EXEL's Days Payable is ranked higher than
90% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. EXEL: 365.72 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 365.72  Med: 872.79 Max: 3050.92
Current: 365.72
365.72
3050.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.30
EXEL's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. EXEL: -16.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -204.5  Med: -11.95 Max: -1.3
Current: -16.3
-204.5
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 237.78
EXEL's Price-to-Tangible-Book is ranked lower than
99% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. EXEL: 237.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.61  Med: 6.57 Max: 437.86
Current: 237.78
3.61
437.86
Price-to-Median-PS-Value 3.18
EXEL's Price-to-Median-PS-Value is ranked lower than
86% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. EXEL: 3.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.11 Max: 4.14
Current: 3.18
0.24
4.14
Earnings Yield (Greenblatt) % -0.62
EXEL's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. EXEL: -0.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.65  Med: 12.5 Max: 17.5
Current: -0.62
-0.65
17.5

More Statistics

Revenue (TTM) (Mil) $191.5
EPS (TTM) $ -0.31
Beta2.65
Short Percentage of Float5.74%
52-Week Range $3.64 - 23.49
Shares Outstanding (Mil)290.87

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 320 514 760
EPS ($) 0.06 0.38 0.87
EPS without NRI ($) 0.06 0.38 0.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
46.00%
Dividends per Share ($)
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
Top Performing Contest Portfolios from 2016 Jan 17 2017 
7 Stocks Outperforming the Market Jan 12 2017 
Why You Should Be Using the Altman Z-Score Dec 18 2016 
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 

More From Other Websites
Exelixis to Present at the Needham & Company Healthcare Conference on April 4 Mar 27 2017
Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : March 27, 2017 Mar 27 2017
When Profit Makers Can Be Active Profit Takers Mar 16 2017
Coverage initiated on Exelixis by Oppenheimer Mar 16 2017
ETFs with exposure to Exelixis, Inc. : March 6, 2017 Mar 06 2017
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma Mar 06 2017
EXELIXIS, INC. Financials Mar 03 2017
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales... Mar 03 2017
Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis Mar 02 2017
Exelixis Announces Webcasts of Investor Conference Presentations in March Mar 01 2017
M&As, Pipeline Catalysts to Drive Pharma Sector Mar 01 2017
Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017 Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)